Hims & Hers Health delivered a first-quarter report that underscored both the strength of its top line and the strain on its margins. Revenue came in around $616.8 million, near the high end of the company’s guidance and ahead of the roughly $616.9 million analysts expected. That marked year-over-year growth of about 28%, a solid result on its own, but one that also highlighted how sharply expansion has cooled from the triple-digit pace the company posted a year earlier.
The bigger issue was profit. Analysts had expected earnings per share of $0.04, down from $0.20 in the same quarter last year, and the company’s results were broadly in line with that view. For investors, the quarter reinforced a familiar tension: Hims & Hers is still growing quickly, but that growth is becoming more expensive.
The company’s recent momentum in categories such as weight loss, along with continued investment in platform development and customer acquisition, appears to be weighing on profitability. International expansion is another major factor. Hims & Hers has been pushing beyond its core U.S. business through acquisitions and broader product rollout, betting that near-term margin pressure will support a larger global revenue base over time.
That strategy is not without logic. Hims & Hers has already built meaningful scale in categories such as sexual health and dermatology, and those businesses have helped fund expansion into newer areas. Management has also laid out an ambitious target for international operations, aiming to generate more than $1 billion in annual revenue from overseas markets within three years while reaching break-even in the nearer term after recent deals close.
Still, the latest quarter suggests investors may need to reset expectations on how smooth that transition will be. Revenue growth remains healthy, but it is slowing as the business matures, and the earnings profile is moving in the opposite direction. That combination tends to draw closer scrutiny, especially for a company that has commanded a premium valuation based on future growth.
The market had already signaled how much was riding on this report. Shares had surged more than 48% in the week before earnings, reflecting aggressive positioning ahead of the release. Such a sharp move left little room for disappointment, and the quarter offered enough mixed signals to keep debate alive over whether Hims & Hers can sustain its growth narrative without sacrificing too much profitability along the way.
The company’s full-year revenue outlook of $2.7 billion to $2.9 billion remains an important anchor. If management can hold that range while showing that margins stabilize in coming quarters, investors may be more willing to look through the current earnings compression. If costs continue to rise faster than revenue, however, the valuation could come under pressure.
What matters now is less the headline revenue number than the path underneath it. Investors will be watching for signs that newer offerings, particularly weight loss, can scale efficiently, and that international expansion begins to show measurable returns. A clearer timeline for margin recovery would also help.
Hims & Hers is no longer being judged simply as a fast-growing telehealth story. It is being judged on execution, capital discipline and the credibility of its longer-term profit model. The first quarter did not break that story, but it did make the next few quarters far more important.